1.Orenstein, WA, Markowitz, L.Preblud, SR, Hinman, AR, Tomasi, A, Bart, KJ. Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986; 65: 13–21.
2.Wilkins, J, Wehrle, PF. Evidence for reinstatement of infant 12 to 14 months of age into routine measles immunization programs. Am J Dis Child 1978; 132: 164–6.
3.Yuan, L. Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. Can Med Assoc J 1994; 150: 1093–8.
4.Christenson, B, Bottiger, M.Heller, L. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: first experience. BMJ 1983; 287: 389–91.
5.Department of Health. Immunisation against infectious disease. London: HMSO, 1992.
6.Recommended childhood immunization schedule: United States, January 1995. MMWR 1995; 43: 959–60.
7.National Advisory Committee on Immunization. Canadian immunization guide. 4th ed.Ottawa: Dept of National Health and Welfare, 1994.
8.Albrecht, P.Ennis, FA.Saltzman, EJ.Krugman, S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977; 91: 715–18.
9.Black, FL. Measles active and passive immunity in a worldwide perspective. Prog Med Virol 1989; 36: 1–33.
10.Boulianne, N, De Serres, G, Duval, B et al. , Major measles outbreak in the Quebec City area in spite of a 99% vaccine coverage. Can J Pub Hlth 1991; 82: 189–90.
11.National Advisory Committee on Immunization. Guidelines for measles control in Canada. Can Dis Weekly Rep 1991; 17: 35–40.
12.Miettinen, O. Estimation and estimability in case-referent studies. Am J Epidemiol 1976; 103: 226–35.
13.Orenstein, WA.Bernier, RH.Hinman, AR. Assessing vaccine efficacy in the field. Epidemiol Rev 1988; 10: 212–41.
14.Halloran, ME.Haber, M.Longini, LM Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992; 136: 328–43.
15.Marks, JS.Hayden, GF.Orenstein, WA. Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs 15 months. Am J Epidemiol 1982; 116: 510–23.
16.Mast, EE.Berg, JL.Hanrahan, LP.Wassell, JT.Davis, JP. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA 1990. 264: 2529–33.
17.King, GE.Markowitz, LE.Patriarca, PA.Dales, LG. Clinical effieacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10: 883–8.
18.Chen, RT.Markowitz, LE.Albrecht, P et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162: 1036–42.
19.Bin, D.Zhihui, C.Qichang, L et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang province, China Bull WHO 1991; 69: 415–23.
20.McLean, ME.Walsh, PJ.Carter, AO.Lavigne, PM. Measles in Canada – 1989. Can Dis Weekly Rep 1990; 16: 213–18.
21.Wong, T.Lee-Han, H.Bell, B.Daley, J.Bailey, N.Vanderpol, M. Measles epidemic in Waterloo region. Ontario. 1990 1991. Can Dis Weekly Rep 1991; 17: 219–24.
22.Gustafson, TL.Lievens, AW.Brunell, PA.Moellenberg, RG.Buttery, CMG.Sehulster, LM. Measles outbreak in a fully immunized secondary school population. N Engl J Med 1987; 316: 771–4.
23.Rosenthal, SR.Clements, CJ. Two-dose measles vaccination schedules. Bull WHO 1993; 71: 421–8.
24.Markowitz, LE.Preblud, SR.Fine, PEM.Orenstein, WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990; 9: 101–10.
25.Colin, ML.Robinson, ED.Faerber, M et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr Infect Dis J 1994; 13: 34–8.